CytomX outlines Varseta-M registrational start in H1 2027 while projecting cash runway into H2 2028 (NASDAQ:CTMX)
· seekingalpha.com
CytomX (CTMX) Q2 2026 earnings call: Varseta-M CRC and GI cancer expansion, key trial timelines, safety, and cash runway to 2028—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...